Prospective, Multi-Center, Observational, Program to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation

Trial Profile

Prospective, Multi-Center, Observational, Program to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Ankylosing spondylitis; Psoriatic arthritis
  • Focus Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 11 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 13 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top